Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cycloleucine is a non-metabolizable synthetic amino acid formed by the cyclization of leucine. It acts as a specific and reversible inhibitor of nucleic acid methylation, particularly by inhibiting S‑adenosyl-methionine-mediated methylation. Cycloleucine is also an antagonist at the glycine site of the NMDA (N-methyl-D-aspartic acid) receptor and has been shown to have cytostatic, antineoplastic, immunosuppressive, and anxiolytic effects in preclinical studies. It is widely used as a research tool in neuroscience, protein synthesis studies, plant biology, and biochemical research to investigate enzyme mechanisms and metabolic pathways[1][2][3][4][5][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cycloleucine.